Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +3.06%8 3-1 Month Momentum % is 12.46% as of Aug. 24, 2026. GuruFocus rates ANL with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Adlai Nortye ranks better than 79.87% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-24), Adlai Nortye's 3-1 Month Momentum % is 12.46%.
The industry rank for Adlai Nortye's 3-1 Month Momentum % or its related term are showing as below:
ANL's 3-1 Month Momentum % is ranked better than 79.87% of 1386
companies
in the Biotechnology industry
Industry Median: -7.29
vs ANL: 12.46
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Adlai Nortye 3-1 Month Momentum % Related Terms
ANL vs REPL, SLDB, ANNX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Adlai Nortye's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a 3-1 Month Momentum % of 12.46% as of Aug. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #279 out of 1386 companies in the Biotechnology industry, placing it in the top 20.1%.
Is Adlai Nortye's 3-1 Month Momentum % too high?
Adlai Nortye's current 3-1 Month Momentum % is 12.46%. Based on the distribution chart, Adlai Nortye ranks #279 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adlai Nortye has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's 3-1 Month Momentum % compare to REPL and SLDB?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #279 out of 1386 companies for 3-1 Month Momentum %. This places Adlai Nortye in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current 3-1 Month Momentum % is 12.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current 3-1 Month Momentum % of 12.46%. The current 3-1 Month Momentum % is 12.46%. Adlai Nortye's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current 3-1 Month Momentum % is 12.46% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
8GF Score
Get the complete analysis for ANL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
